Sign In
Buy GDRX
$2.57
-0.0900 (-3.38%)
At Close: Jun 22, 2026
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced it has earned its 2026 certification status for HITRUST i1 Cert
60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
08:01am, Monday, 02'nd Feb 2026
GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine) Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company's marketing strategy Partners
GoodRx Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call
04:05pm, Wednesday, 28'th Jan 2026
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for prescription savings in the U.S., today announced it will rele
GoodRx Holdings, Inc. (GDRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
07:55pm, Tuesday, 13'th Jan 2026
GoodRx Holdings, Inc. (GDRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Surescripts and GoodRx Partner to Advance Patient Price Transparency
08:00am, Tuesday, 13'th Jan 2026
ARLINGTON, Va. & SANTA MONICA, Calif.--(BUSINESS WIRE)-- #HealthIT--Surescripts®, the nation's leading health intelligence network, introduces its Patient Experience product, Script Corner™, to tra
GoodRx Launches RxSmartSaver at Giant Eagle Pharmacies
09:00am, Thursday, 08'th Jan 2026
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the launch of RxSmartSaver powered by GoodRx at Giant Eagle pharm
GoodRx Now Offers Novo Nordisk's Cash Price for the Launch of the Wegovy® Pill
08:05am, Monday, 05'th Jan 2026
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that the newly FDA-approved Wegovy® pill (oral semaglutide) is n
Q Biomed (OTCMKTS:QBIO) & GoodRx (NASDAQ:GDRX) Financial Survey
02:18am, Saturday, 03'rd Jan 2026
Q Biomed (OTCMKTS:QBIO - Get Free Report) and GoodRx (NASDAQ: GDRX - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the st
COMPASS Pathways (NASDAQ:CMPS) and GoodRx (NASDAQ:GDRX) Financial Analysis
01:58am, Sunday, 21'st Dec 2025
COMPASS Pathways (NASDAQ: CMPS - Get Free Report) and GoodRx (NASDAQ: GDRX - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies
Head to Head Analysis: Embecta (NASDAQ:EMBC) vs. GoodRx (NASDAQ:GDRX)
03:42am, Thursday, 18'th Dec 2025
Embecta (NASDAQ: EMBC - Get Free Report) and GoodRx (NASDAQ: GDRX - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on th
GoodRx to Participate in the 44th Annual J.P. Morgan Healthcare Conference
04:05pm, Tuesday, 16'th Dec 2025
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for medication savings in the U.S., today announced that executive
HIMS vs. GDRX: Which Consumer Health Stock Offers Greater Upside?
01:41pm, Friday, 28'th Nov 2025
Hims & Hers and GoodRx are reshaping virtual care, but which one leads in platform strategy and patient engagement? Let's dive in.
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced two major initiatives to make FDA-approved GLP-1 medications more
GoodRx Holdings, Inc. (GDRX) Q3 2025 Earnings Call Transcript
02:31pm, Wednesday, 05'th Nov 2025
GoodRx Holdings, Inc. ( GDRX ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Aubrey Reynolds - Director of Investor Relations Wendy Barnes - President, CEO & Director Christo
GoodRx Sees ‘Profund Transformation' in Prescriptions With TrumpRx
01:46pm, Wednesday, 05'th Nov 2025
GoodRx CEO Wendy Barnes sees a “profound transformation” happening in prescription drug pricing. The catalyst, Barnes said during an earnings call Wednesday (Nov. 3), is the pending launch of Tr
